Results from up to 10 years follow-up of Episealer® patients accepted for presentation at international orthopaedic congress
Episurf Medical (Nasdaq: EPIS B) today announces that the abstract “Survivorship and clinical outcome of a novel personalized metal implant for the treatment of cartilage lesions of the knee”, by Dr.ssa Francesca de Caro has been accepted for a podium presentation at The Partial Knee Meeting 2024. The congress will take place in Antwerp, Belgium, on January 25-26, 2024.
The abstract reports on high implant survival rate and good clinical outcome for 22 patients who were treated with Episurf Medical’s personalised implant Episealer® Knee as treatment for chondral and osteochondral defects in the knee during 2013 - 2023, at AZ Monica Hospital, Antwerp, Belgium.
“We appreciate the continued interest in the clinical outcome for patients treated with our Episealer® Knee implants. This congress has a focus on the large orthopaedic segment of unicompartmental and patellofemoral replacements for osteoarthritis. The acceptance of this abstract for presentation further confirms that surgeons traditionally more focused on prosthesis surgery, now also show an interest in our less invasive, joint-preserving treatment alternative. We believe we are leading the development globally of smaller implants, hence we are excited about this presentation. Further, this is the first presentation of clinical data where Episealer® patients treated 10 years ago are included. The aim is, of course, to start talking about long-term data for the Episealer®, which is some kind of ultimate goal. This is an important step on the way,” says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on 16 January 2024.
Tags: